Sorry, I don't understand your search. ×
Back to Search Start Over

P1030: MANIFEST-2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL STUDY OF PELABRESIB (CPI-0610) AND RUXOLITINIB VS PLACEBO AND RUXOLITINIB IN JAK INHIBITOR-NAÏVE MYELOFIBROSIS PATIENTS

Authors :
C. Harrison
R. K. Rampal
V. Gupta
S. Verstovsek
M. Talpaz
J.-J. Kiladjian
R. Mesa
A. Kuykendall
A. Vannucchi
F. Palandri
S. Grosicki
T. Devos
E. Jourdan
M. J. Wondergem
H. K. Al-Ali
V. Buxhofer-Ausch
A. Alvarez-Larrán
S. Akhani
R. Muñoz-Carerras
Y. Sheykin
G. Colak
M. Harris
J. Mascarenhas
Source :
HemaSphere, Vol 6, Pp 920-921 (2022)
Publication Year :
2022
Publisher :
Wiley, 2022.

Subjects

Subjects :
Diseases of the blood and blood-forming organs
RC633-647.5

Details

Language :
English
ISSN :
25729241
Volume :
6
Database :
Directory of Open Access Journals
Journal :
HemaSphere
Publication Type :
Academic Journal
Accession number :
edsdoj.f127d6db2a402884aca6d47ada7a18
Document Type :
article
Full Text :
https://doi.org/10.1097/01.HS9.0000846988.26018.ea
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details